Decision Resources, one of the world's leading research and advisory firms
focusing on pharmaceutical and healthcare issues, finds that Teva
Pharmaceutical's Copaxone has the greatest patient share among first- and
second-line therapies, and falls short of Merck Serono/Pfizer's Rebif (by 0.2
percent) in third-line treatment. However, in all three lines of therapy, the
interferon-beta drug class (Biogen Idec's Avonex, Rebif, and Berlex's Betaseron)
outpaces the altered peptide ligand drug class (consisting only of Copaxone) in
patient share. Competition between the two drug classes is fiercest in
"The low volume of patient share attributed to Avonex
or Rebif compared with Copaxone in first and second-line treatment illustrates a
significant delay on the part of physicians and/or patients to engage in an
interferon- beta therapy within a year of a patient's initial diagnosis for
multiple sclerosis," said Madhuri Borde, analyst at Decision Resources.
"However, the magnitudes of Rebif's first- and second-line patient shares
suggest that some physicians are treating the disease more aggressively than
might be expected, as this high-dose, high-frequency agent reaches patient
shares close to and surpassing Avonex in first- and second-line treatment,
According to the new report entitled Treatment Algorithms
in Multiple Sclerosis, neurologists note that Copaxone's better short-term and
long-term side-effect/safety profile, together with its lower rate of induction
of neutralizing antibodies, are critical reasons for choosing Copaxone instead
of Avonex, Rebif and Betaseron. Although Copaxone is administered daily, 23-28
percent of neurologists we surveyed indicate that a key reason to prescribe the
drug over any of the interferon-beta therapies is the drug's ability to foster
greater patient compliance, an attribute that is closely tied to the Copaxone's
lower incidence of flulike side effects.About Treatment Algorithm
Decision Resources combines in-depth primary research
with the most extensive claims-based longitudinal patient-level data from
PharMetrics(R) to provide exceptional insight into physicians' prescribing
trends and the factors that drive therapy product choice, from diagnosis through
multiple courses of treatment, for a specific disease.For each
disease examined, Decision Resources' Treatment Algorithm Insight Series provide
-- Summary of U.S. medical practice based on
interviews with leading experts in the field.
diagnosis/referral/treatment algorithm for the United States.
usage by lines of therapy (1st, 2nd, 3rd line).
-- Discussion of key
freeform combinations by lines of therapy.
-- Product share (class and
specific compound level) within each line of therapy (1st, 2nd, 3rd
-- Progression of therapy from key 1st line products.
Pathway to key therapies from previous therapies.
-- Qualitative analysis
of two-year forecast incorporating upcoming launches, changes in reimbursement,
etc.About Decision Resources
Decision Resources, Inc., (http://www.decisionresources.com
) is a world leader in
healthcare market research publications, advisory services, and consulting
designed to help clients shape strategy, allocate resources, and master their
chosen markets.All company, brand, or product names contained in this
document may be trademarks or registered trademarks of their respective